A novel inhibitor of B-cell lymphoma-2:lisaftoclax
Chronic lymphocytic leukaemia(CLL)and small lymphocytic lymphoma(SLL)are common haematological tumour diseases.Lisaftoclax is an inhibitor of B-cell lymphoma-2(Bcl-2),a key apoptosis-regulating protein that is highly expressed in haematological malignancies.In early clinical trials,lisaftoclax demonstrated promising efficacy and safety,with no dose-limiting toxicity observed even at 1200 mg.The drug is currently in the recruitment phase of a phase Ⅲ clinical trial.This article provides an overview of the basic information,mechanism of action,pharmacokinetics,efficacy,and safety of the drug.
lisaftoclaxinhibitor of B-cell lymphoma-2chronic lymphocytic leukaemiasmall lymphocytic lymphoma
NETL
NSTL
万方数据
